Lund, Sweden, 16 March 2018, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that its Chief Medical Officer Magnus Hansson will present the company's non-alcoholic st ...

Lund, Sweden, 6 March 2018, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) participates in the Stockholm Corporate Finance Life Science Seminar at Operaterassen on 7 March 2018 at 1 ...

Lund, Sweden, 3 January 2018 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), today announced that the company is scheduled to present the 10th Annual Biotech Showcase Conference, ...

Lund, Sweden, 15 November 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the company will present data from its clinical phase IIa study on traumatic bra ...

Lund, Sweden, 2 May 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) ("NeuroVive") invites to a conference call and webcast tomorrow, 3 May 2017, at 2:00 pm CEST, to present th ...

On 25 November, Mikael Brönnegård from NeuroVive was a speaker at a keynote investment event in Gothenburg, arranged by the Swedish Association of Share Investors at the Swedish Exhibition & Conferenc ...

Lund (Sweden) - March 4th, 2013, NeuroVive Pharmaceutical AB, a leading mitochondrial medicine company, announces that Mikael Brönnegård, Chief Executive Officer, will present an overview of its clini ...